- Home
- LWAY vs NNNN Comparison
LWAY vs NNNN Comparison
Compare LWAY & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAY
- NNNN
- Stock Information
- Founded
- LWAY 1986
- NNNN 2021
- Country
- LWAY United States
- NNNN Germany
- Employees
- LWAY N/A
- NNNN N/A
- Industry
- LWAY Packaged Foods
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LWAY Consumer Staples
- NNNN Health Care
- Exchange
- LWAY Nasdaq
- NNNN Nasdaq
- Market Cap
- LWAY 372.2M
- NNNN 369.6M
- IPO Year
- LWAY 1987
- NNNN 2025
- Fundamental
- Price
- LWAY $25.95
- NNNN $36.20
- Analyst Decision
- LWAY Hold
- NNNN
- Analyst Count
- LWAY 1
- NNNN 0
- Target Price
- LWAY N/A
- NNNN N/A
- AVG Volume (30 Days)
- LWAY 44.5K
- NNNN 179.1K
- Earning Date
- LWAY 08-12-2025
- NNNN 01-01-0001
- Dividend Yield
- LWAY N/A
- NNNN N/A
- EPS Growth
- LWAY N/A
- NNNN N/A
- EPS
- LWAY 0.67
- NNNN 0.06
- Revenue
- LWAY $188,277,000.00
- NNNN $8,185,146.00
- Revenue This Year
- LWAY $12.53
- NNNN N/A
- Revenue Next Year
- LWAY $12.08
- NNNN N/A
- P/E Ratio
- LWAY $38.07
- NNNN $643.89
- Revenue Growth
- LWAY 12.84
- NNNN 21.95
- 52 Week Low
- LWAY $10.06
- NNNN $5.18
- 52 Week High
- LWAY $27.29
- NNNN $37.08
- Technical
- Relative Strength Index (RSI)
- LWAY 69.21
- NNNN N/A
- Support Level
- LWAY $23.77
- NNNN N/A
- Resistance Level
- LWAY $25.00
- NNNN N/A
- Average True Range (ATR)
- LWAY 0.73
- NNNN 0.00
- MACD
- LWAY 0.04
- NNNN 0.00
- Stochastic Oscillator
- LWAY 100.00
- NNNN 0.00
About LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.